Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services entities : Transcode therapeutics inc save search
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
TransCode Therapeutics Reports 2023 Results; Provides Business Update
Published: 2024-04-03 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -1.04%
H: 1.48%
C: -3.7%
business update therapeutics
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Published: 2024-03-28 (Crawled : 12:30) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.6%
C: 0.6%
medical therapeutics
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
Published: 2024-03-11 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 2.86%
H: 0.0%
C: -11.14%
report genomics cancer treatment technology therapeutics
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 0.57%
H: 3.69%
C: 3.69%
europe congress leaders therapeutics
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 1.87%
H: 0.0%
C: -1.84%
patent agonist publication application therapeutics
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 4.2%
H: 4.17%
C: -5.26%
nasdaq therapeutics market
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 14.42%
H: 1.21%
C: -10.29%
cancer collaboration therapeutics
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -2.63%
H: 16.15%
C: -3.96%
million offering therapeutics
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
Published: 2024-01-18 (Crawled : 19:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -8.44%
H: 1.2%
C: -18.33%
million offering therapeutics
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
Published: 2024-01-12 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
ceo therapeutics
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 45.93%
C: 10.57%
therapeutics
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -5.66%
H: 0.0%
C: -2.67%
therapeutics
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 11.94%
H: 0.0%
C: -19.05%
mc138 pre-clinical animal positive cancer pancreatic therapeutics results
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
Published: 2023-12-12 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 11.94%
H: 0.0%
C: -19.05%
mc138 ttx-mc138 pre-clinical positive cancer pancreatic therapeutics results
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-05 (Crawled : 14:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -0.88%
H: 4.87%
C: 4.87%
breast symposium cancer therapeutics
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -0.88%
H: 4.87%
C: 4.87%
nasdaq direct offering therapeutics
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
Published: 2023-11-14 (Crawled : 22:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -1.26%
H: 2.08%
C: -8.18%
business update therapeutics
TransCode Therapeutics Withdraws Public Offering
Published: 2023-10-30 (Crawled : 21:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: 11.14%
H: 5.88%
C: -7.45%
offering therapeutics
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
RNAZ | $0.502 0.1% 3.46% 270K
|
Professional, Scientific, and T...
|
| O: -30.22%
H: 24.7%
C: 12.33%
nasdaq extension grants therapeutics market
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.